Treatment
Rapcabtagene autoleucel clinical trials
We’re tracking 6 recruiting studies that include Rapcabtagene autoleucel, each written for real people, not researchers, below.
Recruiting studies
- NCT06655896RecruitingPhase 2
Rapcabtagene Autoleucel for severe diffuse scleroderma
This trial tests an investigational cell therapy called rapcabtagene autoleucel for people with severe diffuse cutaneous systemic sclerosis (a type of scleroderma that affects the skin and internal organs). The treatment uses your own modified immune cells to potentially calm the disease activity.
Los Angeles, CaliforniaAges 18–70 - NCT06868290RecruitingPhase 2
CAR-T cell therapy for severe GPA or MPA
This trial tests a new CAR-T cell treatment (rapcabtagene autoleucel) for people with severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA). It aims to see if this therapy can help control the disease by targeting certain immune cells.
Aurora, ColoradoAges 18–75 - NCT07048197RecruitingPhase 1/Phase 2
Study of cell therapy for rheumatoid arthritis and Sjogren's disease
This trial tests a new cell therapy (Rapcabtagene Autoleucel) to see if it's safe and might help people with rheumatoid arthritis or Sjogren's disease who haven't responded to standard treatments.
BordeauxAges 18–75 - NCT06581198RecruitingPhase 2
CAR-T cell therapy for lupus or lupus nephritis
This trial tests a new CAR-T cell treatment called rapcabtagene autoleucel for people with active lupus or lupus nephritis that hasn't improved with at least two standard therapies. It aims to reduce disease activity and may offer a new option for hard-to-treat cases.
Birmingham, AlabamaAges 18–75 - NCT06617793RecruitingPhase 1/Phase 2
Testing YTB323 for active relapsing multiple sclerosis
This trial tests a new cell therapy called YTB323 for people with relapsing multiple sclerosis (RMS) that is still active despite strong treatments. The treatment aims to reset the immune system to stop attacks on nerves.
Darlinghurst, New South WalesAges 18–60 - NCT06675864RecruitingPhase 1/Phase 2
YTB323 for non-active progressive MS
This trial tests a new treatment called YTB323, which is a type of personalized cell therapy (CAR-T) designed to target your immune system and slow down MS progression. It is for people with non-active progressive MS who have seen their disability worsen recently.
Darlinghurst, New South WalesAges 18–60
What Rapcabtagene autoleucel is being studied for
Conditions with recruiting Rapcabtagene autoleucel studies.
Common questions
- Are there clinical trials studying Rapcabtagene autoleucel?
- Yes. Clin2 currently lists 6 recruiting studies that include Rapcabtagene autoleucel, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Rapcabtagene autoleucel trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Rapcabtagene autoleucel an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Rapcabtagene autoleucel or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.